Enanta Pharmaceuticals, Inc. (ENTA)
12.50
+0.40
(+3.31%)
USD |
NASDAQ |
Oct 09, 16:00
12.48
-0.02
(-0.12%)
After-Hours: 20:00
Enanta Pharmaceuticals Cash from Operations (Quarterly) : -9.972M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.972M |
| March 31, 2026 | -7.156M |
| December 31, 2025 | -11.70M |
| September 30, 2025 | -6.489M |
| June 30, 2025 | 17.51M |
| March 31, 2025 | -13.49M |
| December 31, 2024 | -16.80M |
| September 30, 2024 | -10.40M |
| June 30, 2024 | -14.78M |
| March 31, 2024 | -28.60M |
| December 31, 2023 | -24.99M |
| September 30, 2023 | -21.60M |
| June 30, 2023 | -32.13M |
| March 31, 2023 | -13.78M |
| December 31, 2022 | -35.64M |
| September 30, 2022 | -15.53M |
| June 30, 2022 | -29.60M |
| March 31, 2022 | -26.38M |
| December 31, 2021 | -13.27M |
| September 30, 2021 | -21.02M |
| June 30, 2021 | -29.51M |
| March 31, 2021 | -4.579M |
| December 31, 2020 | -14.89M |
| September 30, 2020 | -15.46M |
| June 30, 2020 | -4.488M |
| Date | Value |
|---|---|
| March 31, 2020 | 14.67M |
| December 31, 2019 | 12.36M |
| September 30, 2019 | 8.545M |
| June 30, 2019 | 2.533M |
| March 31, 2019 | 30.09M |
| December 31, 2018 | 30.25M |
| September 30, 2018 | 28.34M |
| June 30, 2018 | 4.048M |
| March 31, 2018 | -7.578M |
| December 31, 2017 | 4.409M |
| September 30, 2017 | 57.31M |
| June 30, 2017 | -4.796M |
| March 31, 2017 | -3.002M |
| December 31, 2016 | 3.145M |
| September 30, 2016 | -2.126M |
| June 30, 2016 | -2.112M |
| March 31, 2016 | 10.05M |
| December 31, 2015 | 29.99M |
| September 30, 2015 | -2.375M |
| June 30, 2015 | -14.20M |
| March 31, 2015 | 98.86M |
| December 31, 2014 | -5.61M |
| September 30, 2014 | -4.932M |
| June 30, 2014 | 35.11M |
| March 31, 2014 | -4.13M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | -20.65M |
| Coherus Oncology, Inc. | -62.09M |
| BridgeBio Pharma, Inc. | -71.10M |
| RenovoRx, Inc. | -2.867M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 14.00M |
| Cash from Financing (Quarterly) | -5.542M |
| Free Cash Flow | -36.94M |
| Free Cash Flow Per Share (Quarterly) | -0.343 |
| Free Cash Flow to Equity (Quarterly) | -5.402M |
| Free Cash Flow to Firm (Quarterly) | -5.841M |
| Free Cash Flow Yield | -10.92% |